Treatment
S-1 clinical trials
We’re tracking 802 recruiting studies that include S-1, each written for real people, not researchers, below.
Recruiting studies
- NCT05215704Recruiting
Lab study of dormant HIV using samples from you
This trial collects blood samples from people living with HIV to study dormant (inactive) HIV cells in the lab. The goal is to better understand how to target these hidden cells as part of an eventual cure.
RotterdamAges 18 years+ - NCT05218889RecruitingPhase 1/Phase 2
Surufatinib plus immunotherapy for advanced pancreatic cancer
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
BeijingAges 18–75 - NCT05236972RecruitingPhase 3
PD-1 antibody after colon cancer surgery for dMMR stage III
This phase 3 trial studies a PD-1 antibody medicine given after surgery to help prevent stage III colon cancer from coming back. It is specifically for people whose tumor is mismatch repair–defective (dMMR) or MSI-H, which may make the cancer more responsive to immune-based treatment.
GuangzhouAges 18–75 - NCT05287464Recruiting
Study for metastatic kidney cancer treatments combinations
This trial studies people with advanced (metastatic) kidney cancer who are starting a specific set of first-line treatment combinations (including drugs like nivolumab, pembrolizumab, or avelumab, paired with targeted medicines). It may help improve how these treatment plans work for different types of kidney cancer.
Province of Macerata, MacerataAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT05308628Recruiting
Tests for liver scar (fibrosis) in children after liver transplant
This study checks how well a liver “fibrosis panel” test can evaluate scarring in children who have had their first liver transplant. Your child may be helped by getting extra monitoring of liver scarring, and the study may improve how doctors assess recovery and risk over time.
ShanghaiAges 2 months–18 years - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05335811RecruitingPhase 1
PET scan test of a new radioactive drug for tumors and inflammation
This Phase 1 study tests whether a new PET imaging tracer (a small amount of radioactive medicine) is safe and how it moves through the body. It’s mainly for adults with cancer who have signs of inflammation or possible immune side effects, so doctors can see what’s happening in the body.
Houston, TexasAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05357846RecruitingPhase 3
Check whether PD-1 treatment helps esophagus cancer before surgery
This Phase 3 trial tests whether adding a PD-1 medicine (sintilimab) to standard chemo-radiation before surgery improves outcomes for locally advanced esophageal squamous cell cancer. It may help by strengthening the immune response while shrinking the tumor before an operation.
Guangzhou, GuangdongAges 18–70 - NCT05378490Recruiting
Study of stroke types and thrombolysis treatment
This study includes people who have had certain kinds of sudden brain blood-flow problems (like an ischemic stroke, bleeding in the brain, or a brief warning episode) or conditions that look similar. It looks at how treatment such as clot-busting medicine (thrombolysis) fits for these situations.
LørenskogAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05430698RecruitingPhase 2
PD-1 antibody after surgery for bile duct cancer
This Phase 2 trial studies whether adding a PD-1 antibody plus gemcitabine/oxaliplatin (GEMOX) after surgery can lower the chance of the cancer coming back in perihilar cholangiocarcinoma. It’s for people who have had surgery with no tumor left at the cut edges, but lymph nodes showed cancer under the microscope.
Guangzhou, GuangdongAges 18–75 - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT05467748RecruitingPhase 1/Phase 2
Study drug combo for advanced lung cancer after PD-1 treatment
This Phase 1/2 trial tests a combination of an EZH2 inhibitor (tulmimetostat) with a PD-1 blocker (pembrolizumab) for advanced non-small cell lung cancer that has stopped responding to prior PD-1 treatment. It may help shrink or control cancer and is mainly aimed at people who have limited treatment options left.
Long Beach, CaliforniaAges 18 years+ - NCT05470127Recruiting
Testing a new prostate biopsy needle against the usual one
This study compares a new prostate biopsy system/needle with the standard biopsy needle during your scheduled prostate biopsy. It looks at how well the procedure collects tissue for diagnosis and how the tissue samples compare.
Cartersville, GeorgiaAges 18–90 - NCT05496036RecruitingPhase 2
Pembrolizumab before surgery for resectable Merkel cell cancer
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05590455RecruitingPhase 2
Testing a TNF-blocking drug to reduce death in HIV and TB meningitis
This Phase 2 trial studies whether a TNF-blocking medicine can lower the risk of death in people with HIV who also have TB meningitis. You would receive standard TB meningitis treatment plus the study drug, if you meet the criteria.
Rio de JaneiroAges 18 years+ - NCT05628038RecruitingPhase 2
Radiation plus immunotherapy for recurrent rectal cancer
This Phase 2 trial tests whether giving targeted radiation and an immunotherapy drug together can control locally recurring rectal cancer in the pelvis. It may help shrink tumors and slow disease growth, especially after certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05636540RecruitingEarly Phase 1
PET/CT scan test for a tumor protein in these rare tumors
This early study uses a special PET/CT scan to see how much a specific cancer-related protein (PARP-1) is present in pheochromocytoma and paraganglioma. It may help doctors understand the biology of these tumors and how useful this scan could be in the future.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05653973RecruitingEarly Phase 1
Testing aspirin’s effects on blood vessel function after pregnancy
This early study looks at how taking aspirin (or not) affects how well blood vessels work after pregnancy. It may help researchers understand differences in vascular health after normal pregnancies versus preeclampsia (a pregnancy blood pressure complication).
Iowa City, IowaAges 18–50
Common questions
- Are there clinical trials studying S-1?
- Yes. Clin2 currently lists 802 recruiting studies that include S-1, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a S-1 trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is S-1 an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether S-1 or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.